Viral Diseases Tester Virax Biolabs Prices Upsized US$6.75 Million IPO

Biopharmaceutical company Virax Biolabs Group Limited recently increased its initial public offering size as it applies for a Nasdaq Capital Market listing. The firm is now looking to raise US$6.75 million.

The offering consists of 1.35 million common shares, up from the previously announced 1.2 million, selling at US$5.00 per share. The company targets to trade on the Nasdaq market under the symbol “VRAX”.

Boustead Securities acts as the sole bookrunner for the said offering. The underwriters were granted a 45-day over-allotment option to purchase additional 202,500 shares at the same IPO price.

Selkirk Copper Mines — sponsored Sponsored · Selkirk Copper Mines

Net proceeds from the offering are expected to be used for research & development, obtaining product certification approvals, expanding staff & payroll, marketing & advertising, working capital, operating expenses, inventory purchases, and regulatory & compliance work.

The UK-based biotech company focuses on developing T-cell testing as a method to detect one’s risk to major global viral threats through immunology profiling. The firm recently received ethical approval for its current study involving its Virax Immune COVID-19 test kit that bases its detection of viral immunity on T-cells instead of antibodies like most other kits.


Information for this briefing was found via Edgar and the companies mentioned. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Seabridge Loses KSM’s Substantially Started Status

This Gold Giant Got Crushed… Now It’s the Cheapest Major | Kinross Gold’s Q3 Earnings

Why I’m Still Bullish on Gold Below $3,900 | Wes Hanson – Thunder Gold

Recommended

Epic Gold Delivers Maiden 279,000 Ounce Inferred Resource at Wilson Project

First Phosphate Adds UK Export Finance to Growing Export Credit Lineup With C$220 Million Letter of Interest

Related News

Tiger Williams-Led SPAC Williams Rowland Acquisition Seeks To Raise US$200 Million In IPO

Special purpose acquisition company Williams Rowland Acquisition Corp. (NYSE: WRACU) went public on the New...

Tuesday, July 27, 2021, 12:21:00 PM

Trump Brothers Give Blank-Check Another Try In A $300M SPAC IPO

New America Acquisition I Corp. promises to “revitalize domestic manufacturing,” yet its biggest beneficiaries at...

Tuesday, August 5, 2025, 08:05:00 AM

Tech SPAC Denali Capital Acquisition Prices US$75 Million IPO

Special purpose acquisition company Denali Capital Acquisition Corp. (Nasdaq: DECAU) started trading publicly on the...

Friday, April 8, 2022, 02:19:00 PM

Video Surveillance Firm Maris-Tech Prices US$15.5 Million Nasdaq IPO

Video transmission technology provider Maris-Tech Ltd. (Nasdaq: MTEK) started trading on the Nasdaq Capital Market...

Wednesday, February 2, 2022, 02:21:00 PM

Biotech Firm HilleVax Prices US$200 Million IPO

Biopharmaceutical company HilleVax, Inc. (Nasdaq: HLVX) began trading on the Nasdaq Global Select Market on...

Monday, May 2, 2022, 02:25:00 PM